No Data
No Data
China Traditional Chinese Medicine, Sinopharm Update on Privatization Process Status
China Traditional Chinese Medicine Holdings (HKG:0570) and Sinopharm Common Wealth jointly announced that Sinopharm's representatives have been preparing required documents, notifications, filings and
中國中藥:2023年年報
Good sector+performance catalyst, explaining in detail the differences in Tongrentang Technology (01666.HK)'s dual market expectations
Under a series of favorable policies, Tong Ren Tang Technology, as a highly recognizable and even scarce enterprise in the Hong Kong stock market, will benefit.
China Traditional Chinese Medicine Posts 94% Profit Growth in 2023
China Traditional Chinese Medicine Holdings Co (HKG:0570) recorded a 93.6% rise in its net profit to 1.40 billion yuan in 2023, against 720.96 million yuan a year ago, according to a Thursday filing w
China Traditional Chinese Medicine announces 2023 annual results, profit attributable to shareholders of 1,285 billion yuan, an increase of 68.11% year-on-year
China Traditional Chinese Medicine (00570) announced annual results for the year ended December 31, 2023. The group achieved a turnover of 18.122 billion yuan (RMB, same below) during the period, an increase of 26.69% over the previous year; profit attributable to shareholders was 1,285 billion yuan, an increase of 68.11% over the previous year; and basic profit per share was 25.52 points.
China Traditional Chinese Medicine (00570.HK)'s annual net profit of 1,396 billion yuan increased 93.6% year-on-year
Gelonghui, March 21, 丨 China Traditional Chinese Medicine (00570.HK) announced that for the year ended December 31, 2023, the company's turnover was RMB 18.1 billion, up 26.7% from the same period in 2022; net profit was RMB 1,396 billion, up 93.6% from the same period in 2022. No dividend payments were recommended for the year.
No Data